Latest Financial Results News

Medical Developments International has posted positive operating cashflow for the first half of FY26, driven by robust growth in its flagship product Penthrox across Australia and Europe, alongside progress in paediatric approvals.

Chalice Mining has completed a pivotal Pre-Feasibility Study for its Gonneville Palladium-Nickel-Copper Project, defining a maiden Ore Reserve and setting sights on a Final Investment Decision by mid-2028 amid robust metal prices.

Lloyds Banking Group reported a robust 2025 performance with a 12% rise in statutory profit before tax and upgraded its 2026 guidance, underpinned by strong loan growth and digital innovation. The Group also announced significant shareholder returns totalling £3.9 billion, including dividends and a share buyback programme.

BKI Investment Company reported a solid half-year performance with a 7% rise in operating results and a 1% increase in fully franked dividends, driven by a strategic portfolio rotation favoring resource stocks aligned with global growth themes.

BKI Investment Company Limited reported a 10% increase in net profit after tax to $34.3 million for the half-year ended 31 December 2025, alongside a modest rise in its interim dividend. The company’s portfolio performance reflected mixed sector trends amid a volatile market.

Immutep Limited has entered a strategic collaboration with Dr. Reddy’s, receiving a A$30 million upfront payment and potential milestones up to A$528 million, while reporting promising clinical progress across multiple cancer immunotherapy trials.

Hawthorn Resources has reported exceptional high-grade drilling results at its Anglo Saxon Gold Project, underpinning a robust updated resource estimate and advancing plans for open pit mining. The company’s strong cash position supports ongoing development amid record gold prices.

Bioxyne Limited has delivered a record-breaking second quarter in FY2026, posting $17.2 million in revenue and expanding its footprint into key international markets. The company’s growth is underpinned by new contracts, innovative psychedelics products, and strategic government funding.

Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.

Liontown Limited has successfully transitioned to 100% underground mining at Kathleen Valley, delivering a 37% increase in underground production and a 91% jump in quarterly revenue. The company is on track to reduce costs and boost recoveries as it targets a steady-state underground run-rate.

Aerometrex Limited has reported record first half revenue and EBITDA for the six months ending December 2025, driven by strong MetroMap subscription growth and a rebound in LiDAR sales.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.